About Us Cisbio Bioassays is a privately held life sciences company committed to improving human healthcare. With more than 30 years of experience in in vitro diagnostics and drug discovery, we provide creative technological solutions and partnerships to the global scientific community. Our portfolio of over 460 proprietary assays and reagents is used by pharmaceutical, biotechnology, academia and contract research organizations worldwide to help generate effective therapies. Research innovation Cisbio Bioassays began as a developer of immunoassays. In the 1990’s, we combined this know-how with Nobel prize-winning chemistry research to create Homogeneous Time Resolved Fluorescence (HTRF®), a breakthrough technology that, to this day, provides advanced properties that enhance and accelerate the drug discovery process. Our R&D teams — both organically and in collaboration with industrial and academic research partners — regularly expand HTRF’s field of applications through new tools that help better understand biological function. Our commitment to service Cisbio Bioassays is a business unit of IBA group and has facilities in France, the United States and China, and a network of sales offices and distributors across the globe. Our relationship with customers is at the core of our activity, and we provide a hands-on approach and collaborative products that contribute to successful drug discovery research projects in every major market. Our in-house and field-based staff of scientific consultants combines a variety of disciplines – from chemistry to molecular and cellular biology – to offer knowledgeable technical services and support on assay development technology education, assay implementation, new applications, overcoming unique challenges, strategic thinking and assay conceptualization. Through our dedication to innovation in technologies, products and associated services, Cisbio Bioassays will continue to respond to the unmet technical needs of customers, as well as the existing and future medical concerns of a global patient base.